For example, patients with BRCA1 mutations are at risk for both bilateral breast disease as well as ovarian carcinoma; thus, women with BRCA1-associated cancers may be offered bilateral mastectomy and/or oophorectomy and may derive more benefit from PARP inhibitors compared to patients with sporadic breast cancer [12]. This evidence concerns the gene BRCA1 and breast carcinoma.